New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

Tom Chalberg, Ph.D., co-founder of Genascence, explains how gene therapies are moving beyond the confines of rare diseases and into a wider range of indications.

Oxygen, crucial for cellular respiration, is affected by pressure variations within a bioreactor, with higher pressure at the bottom leading to increased oxygen solubility. This heterogeneity is ...

Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI ...

LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous ...

Adaptability serves as the foundation for lasting career success, shaping leaders who can thrive in an ever-changing business ...

This article is the second installment of a three-part series aimed at helping drug and device manufacturers better navigate and understand the VA and DOD health systems. The first installment in the ...

Over the last 15 years, biopharmaceutical compliance departments, and chief compliance officers, have been better resourced, with more direct reporting lines to company leadership, than ever before. A ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...